[go: up one dir, main page]

WO2016014992A3 - Compositions pour le traitement, le diagnostic et le pronostic de maladies - Google Patents

Compositions pour le traitement, le diagnostic et le pronostic de maladies Download PDF

Info

Publication number
WO2016014992A3
WO2016014992A3 PCT/US2015/042084 US2015042084W WO2016014992A3 WO 2016014992 A3 WO2016014992 A3 WO 2016014992A3 US 2015042084 W US2015042084 W US 2015042084W WO 2016014992 A3 WO2016014992 A3 WO 2016014992A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
prognosis
diseases
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/042084
Other languages
English (en)
Other versions
WO2016014992A2 (fr
Inventor
Jenny L. PERSSON
Heather H. JOHNSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Everest Biosciences Inc
Original Assignee
Everest Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Everest Biosciences Inc filed Critical Everest Biosciences Inc
Publication of WO2016014992A2 publication Critical patent/WO2016014992A2/fr
Publication of WO2016014992A3 publication Critical patent/WO2016014992A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01068—1-Phosphatidylinositol-4-phosphate 5-kinase (2.7.1.68)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouvelles compositions utiles sur le plan pharmaceutique, qui peuvent être utiles dans le traitement de maladies telles que le cancer. L'invention concerne également l'utilisation de ces compositions pour le diagnostic et le pronostic de maladies, la sélection de traitement et la surveillance de la progression d'une maladie.
PCT/US2015/042084 2014-07-24 2015-07-24 Compositions pour le traitement, le diagnostic et le pronostic de maladies Ceased WO2016014992A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028783P 2014-07-24 2014-07-24
US62/028,783 2014-07-24

Publications (2)

Publication Number Publication Date
WO2016014992A2 WO2016014992A2 (fr) 2016-01-28
WO2016014992A3 true WO2016014992A3 (fr) 2016-03-17

Family

ID=55163985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/042084 Ceased WO2016014992A2 (fr) 2014-07-24 2015-07-24 Compositions pour le traitement, le diagnostic et le pronostic de maladies

Country Status (1)

Country Link
WO (1) WO2016014992A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106544361A (zh) * 2016-12-02 2017-03-29 新乡医学院 哺乳动物细胞表达载体、表达系统、制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12096031B2 (en) 2017-06-05 2024-09-17 Immersive Robotics Pty Ltd. Method and apparatus for digital content stream compression and decompression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114400A1 (en) * 2001-12-06 2003-06-19 Isis Pharmaceuticals Inc. Antisense modulation of phosphatidylinositol-4-phosphate 5-kinase, Ialpha expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114400A1 (en) * 2001-12-06 2003-06-19 Isis Pharmaceuticals Inc. Antisense modulation of phosphatidylinositol-4-phosphate 5-kinase, Ialpha expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI ET AL.: "The ATM Inhibitor KU-55933 Suppresses Cell Proliferation and Induces Apoptosis by Blocking Akt In Cancer Cells with Overactivated Akt.", MOL CANCER THER, vol. 9, no. 1, January 2010 (2010-01-01), pages 113 - 125 *
MUSCOLINI ET AL.: "Phosphatidylinositol 4-Phosphate 5-Kinase alpha Activation Critically Contributes to CD 28-Dependent Signaling Responses.", THE JOURNAL OF IMMUNOLOGY, vol. 190, no. 10, 15 May 2013 (2013-05-15), pages 5279 - 5286 *
VAN DEN BOUT ET AL.: "PIP5K-driven Ptdlns(4,5)P2 synthesis: regulation and cellular function.", J CELL SCI, vol. 122, no. 21, 1 November 2009 (2009-11-01), pages 3837 - 3850 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106544361A (zh) * 2016-12-02 2017-03-29 新乡医学院 哺乳动物细胞表达载体、表达系统、制备方法和应用

Also Published As

Publication number Publication date
WO2016014992A2 (fr) 2016-01-28

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
WO2017030823A3 (fr) Anticorps anti-tigit
EP3448874A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
MD4733B1 (ro) Anticorpi anti-TIGIT
IL264156A (en) Compounds, preparations and methods for treating the disease
WO2016100985A3 (fr) Récepteurs antigéniques chimériques et leurs procédés d'utilisation
EP3177732A4 (fr) Compositions et procédés pour le traitement de maladies et états pathologiques ophthalmiques
WO2015148863A3 (fr) Méthodes liées à crispr/cas et compositions pour le traitement de la drépanocytose
WO2016098079A3 (fr) Compositions et méthodes associées à des anticorps ciblant bmp6
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
EP3182989A4 (fr) Méthodes et compositions destinées à prévenir et à traiter une maladie
CN106659716A8 (zh) 阿吡莫德组合物及其使用方法
WO2015179835A3 (fr) Biomarqueurs mit et leurs méthodes d'utilisation
WO2016106343A8 (fr) Organismes probiotiques pour le diagnostic, la surveillance et le traitement de la maladie intestinale inflammatoire
EP3149192A4 (fr) Procédés et compositions permettant d'utiliser l'élastase neutrophile et la protéinase 3 en tant que biomarqueurs de diagnostic
WO2015120372A3 (fr) Compositions et méthodes d'inhibition de ezh2 pour traiter des maladies cardiovasculaires
WO2016138538A3 (fr) Utilisation thérapeutique d'anticorps de liaison à l'intégrine
WO2016094374A8 (fr) Compositions et méthodes de traitement de l'ataxie de friedreich
WO2015179823A3 (fr) Inhibiteurs d'alpha (v) bêta 6, localisés dans les poumons
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
WO2016014992A3 (fr) Compositions pour le traitement, le diagnostic et le pronostic de maladies
WO2015013233A3 (fr) Procédés et compositions pour le traitement et le diagnostic du cancer de la vessie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15824903

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15824903

Country of ref document: EP

Kind code of ref document: A2